These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.

Barrons • Aug 7, 2026

Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks Investment Research • Aug 6, 2026

U.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second Season

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA™ (clesrovimab-cfor) to expand its indication to include prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in children under two years of age at increased risk for severe RSV disease through their second RSV season.

Business Wire • Aug 6, 2026

After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?

Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) refreshed the dividend debate with their latest quarterly reports.

24/7 Wall Street • Aug 6, 2026

Merck & Co., Inc. Q2 Earnings Call Highlights

Merck & Co., Inc. NYSE: MRK reported second-quarter revenue of $16.6 billion, up 5% from a year earlier, driven by oncology, animal health and contributions from newer product launches. Revenue increased 4% excluding foreign exchange, according to Chief Financial Officer Caroline Litchfield.

MarketBeat • Aug 5, 2026

MRK Q2 Earnings Call Puts Pipeline Progress in Focus

Merck raised its 2026 sales outlook as pipeline gains, new launches and post-KEYTRUDA plans took focus despite acquisition-driven losses.

Zacks Investment Research • Aug 5, 2026

Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal charges

Merck beat second-quarter estimates and hiked its revenue outlook, as a slate of new products showed strong growth.  But the pharmaceutical giant cut its profit guidance due to a charge tied to its acquisition of biotech company Terns Pharmaceuticals.

CNBC • Aug 4, 2026

Merck posts better-than-expected second-quarter results on Keytruda strength

Merck reported higher-than-expected second-quarter sales on Tuesday and raised its full-year revenue forecast on the strength of its top-selling cancer treatment Keytruda.

Reuters • Aug 4, 2026

The Merck Product That Absolutely Demolished Wall Street's Forecasts

Merck's new injectable version of Keytruda walloped sales expectations Tuesday, packing a $200 million-plus punch vs. Wall Street's forecasts.

Investors Business Daily • Aug 4, 2026

Merck Cuts Full-Year Profit Forecast as Acquisition Costs Weigh on Bottom Line

Merck slashed its profit outlook for the year due to charges tied to its acquisition of cancer biotech company Terns Pharmaceuticals.

WSJ • Aug 4, 2026